122 related articles for article (PubMed ID: 38723789)
1. Reduced risk of CIN2+ recurrence in women immunized with a 9-valent HPV vaccine post-excision: Retrospective cohort study.
Dvořák V; Petráš M; Dvořák V; Lomozová D; Dlouhý P; Králová Lesná I; Pilka R
Hum Vaccin Immunother; 2024 Dec; 20(1):2343552. PubMed ID: 38723789
[TBL] [Abstract][Full Text] [Related]
2. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
3. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
[TBL] [Abstract][Full Text] [Related]
4. Risk of cervical intraepithelial neoplasia grade 2 or worse after conization in relation to HPV vaccination status.
Sand FL; Kjaer SK; Frederiksen K; Dehlendorff C
Int J Cancer; 2020 Aug; 147(3):641-647. PubMed ID: 31648368
[TBL] [Abstract][Full Text] [Related]
5. Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomised Costa Rica HPV Vaccine Trial.
Shing JZ; Hu S; Herrero R; Hildesheim A; Porras C; Sampson JN; Schussler J; Schiller JT; Lowy DR; Sierra MS; Carvajal L; Kreimer AR;
Lancet Oncol; 2022 Jul; 23(7):940-949. PubMed ID: 35709811
[TBL] [Abstract][Full Text] [Related]
6. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women.
Joura EA; Giuliano AR; Iversen OE; Bouchard C; Mao C; Mehlsen J; Moreira ED; Ngan Y; Petersen LK; Lazcano-Ponce E; Pitisuttithum P; Restrepo JA; Stuart G; Woelber L; Yang YC; Cuzick J; Garland SM; Huh W; Kjaer SK; Bautista OM; Chan IS; Chen J; Gesser R; Moeller E; Ritter M; Vuocolo S; Luxembourg A;
N Engl J Med; 2015 Feb; 372(8):711-23. PubMed ID: 25693011
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial.
Porras C; Tsang SH; Herrero R; Guillén D; Darragh TM; Stoler MH; Hildesheim A; Wagner S; Boland J; Lowy DR; Schiller JT; Schiffman M; Schussler J; Gail MH; Quint W; Ocampo R; Morales J; Rodríguez AC; Hu S; Sampson JN; Kreimer AR;
Lancet Oncol; 2020 Dec; 21(12):1643-1652. PubMed ID: 33271093
[TBL] [Abstract][Full Text] [Related]
8. Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2-3)?
Kang WD; Choi HS; Kim SM
Gynecol Oncol; 2013 Aug; 130(2):264-8. PubMed ID: 23623831
[TBL] [Abstract][Full Text] [Related]
9. High-grade CIN on cervical biopsy and predictors of the subsequent cone histology results in women undergoing immediate conization.
Giannella L; Mfuta K; Gardini G; Rubino T; Fodero C; Prandi S
Eur J Obstet Gynecol Reprod Biol; 2015 Mar; 186():68-74. PubMed ID: 25656975
[TBL] [Abstract][Full Text] [Related]
10. The impact of human papillomavirus type on colposcopy performance in women offered HPV immunisation in a catch-up vaccine programme: a two-centre observational study.
Munro A; Gillespie C; Cotton S; Busby-Earle C; Kavanagh K; Cuschieri K; Cubie H; Robertson C; Smart L; Pollock K; Moore C; Palmer T; Cruickshank ME
BJOG; 2017 Aug; 124(9):1394-1401. PubMed ID: 28102931
[TBL] [Abstract][Full Text] [Related]
11. Age-specific predictors of cervical dysplasia recurrence after primary conization: analysis of 3,212 women.
Bogani G; Pinelli C; Chiappa V; Martinelli F; Lopez S; Ditto A; Raspagliesi F
J Gynecol Oncol; 2020 Sep; 31(5):e60. PubMed ID: 32808492
[TBL] [Abstract][Full Text] [Related]
12. Human papillomavirus vaccination in women undergoing excisional treatment for cervical intraepithelial neoplasia and subsequent risk of recurrence: A systematic review and meta-analysis.
Eriksen DO; Jensen PT; Schroll JB; Hammer A
Acta Obstet Gynecol Scand; 2022 Jun; 101(6):597-607. PubMed ID: 35470865
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant Human Papillomavirus Vaccine to Reduce Recurrent Cervical Dysplasia in Unvaccinated Women: A Systematic Review and Meta-analysis.
Lichter K; Krause D; Xu J; Tsai SHL; Hage C; Weston E; Eke A; Levinson K
Obstet Gynecol; 2020 May; 135(5):1070-1083. PubMed ID: 32282601
[TBL] [Abstract][Full Text] [Related]
14. The efficacy of human papillomavirus prophylactic vaccination after conization in preventing cervical intraepithelial neoplasia recurrence: A prospective observational study in China.
Chen M; Li C; Cui Q; Zhou C; Chen P; Yao S
Eur J Obstet Gynecol Reprod Biol; 2023 Jul; 286():10-15. PubMed ID: 37159990
[TBL] [Abstract][Full Text] [Related]
15. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of
Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Harjula K; Kuortti M; Natunen K; Palmroth J; Petäjä T; Pukkala E; Siitari-Mattila M; Struyf F; Nieminen P; Paavonen J; Dubin G; Dillner J
BMJ Open; 2017 Aug; 7(8):e015867. PubMed ID: 28821519
[TBL] [Abstract][Full Text] [Related]
16. Role of human papillomavirus (HPV) vaccination on HPV infection and recurrence of HPV related disease after local surgical treatment: systematic review and meta-analysis.
Kechagias KS; Kalliala I; Bowden SJ; Athanasiou A; Paraskevaidi M; Paraskevaidis E; Dillner J; Nieminen P; Strander B; Sasieni P; Veroniki AA; Kyrgiou M
BMJ; 2022 Aug; 378():e070135. PubMed ID: 35922074
[TBL] [Abstract][Full Text] [Related]
17. Trends in Human Papillomavirus Vaccine Types 16 and 18 in Cervical Precancers, 2008-2014.
McClung NM; Gargano JW; Bennett NM; Niccolai LM; Abdullah N; Griffin MR; Park IU; Cleveland AA; Querec TD; Unger ER; Markowitz LE;
Cancer Epidemiol Biomarkers Prev; 2019 Mar; 28(3):602-609. PubMed ID: 30792242
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of HPV vaccination against the development of high-grade cervical lesions in young Japanese women.
Shiko Y; Konno R; Konishi H; Sauvaget C; Ohashi Y; Kakizoe T
BMC Infect Dis; 2020 Nov; 20(1):808. PubMed ID: 33153446
[TBL] [Abstract][Full Text] [Related]
19. Reduction in cervical intraepithelial neoplasia in young women in British Columbia after introduction of the HPV vaccine: An ecological analysis.
Ogilvie GS; Naus M; Money DM; Dobson SR; Miller D; Krajden M; van Niekerk DJ; Coldman AJ
Int J Cancer; 2015 Oct; 137(8):1931-7. PubMed ID: 25754686
[TBL] [Abstract][Full Text] [Related]
20. Risk of progression of cervical intraepithelial neoplasia grade 2 in human papillomavirus-vaccinated and unvaccinated women: a population-based cohort study.
Krog L; Lycke KD; Kahlert J; Randrup TH; Jensen PT; Rositch AF; Hammer A
Am J Obstet Gynecol; 2024 Apr; 230(4):430.e1-430.e11. PubMed ID: 38569830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
